EHA 2021 Top Pick #7: Long Term Results of a Phase I/Ib Study of Ibrutinib in Combination with Umbralisib in Patients with Relapsed/Refractory (R/R) CLL (Chronic Lymphocytic Leukemia) or MCL (Mantle Cell Lymphoma)

You are here: